It came to our knowledge that the United States Food and Drug Administration (FDA) has approved Spiriva® HandiHaler®, the long-acting, once daily inhalation powder.
Boehringer, in connection with Pfizer, expects Spiriva® to be available in the pharmacies by the middle of this year.
Please do not reply to this e-mail as the sender address is not monitored.
Should you wish not to receive our e-Newsletter, please send an e-mail to firstname.lastname@example.org to unsubscribe. Please allow up to 72 hours to remove your e-mail address from our data base.
Click the following link to access our newsletter catalog. From this page you will be able to access all the available newsletters both in HTML and PDF (Adobe's Portable Document Format).
To access the print-equivalent Newletter in PDF you will need to download and install the Adobe PDF Reader. You can access the free download site of Adobe by clicking this icon
Regarding any other issue please send an e-mail to email@example.com